AR052567A1 - Combinacion de bambuterol e inhibidor de integrina - Google Patents

Combinacion de bambuterol e inhibidor de integrina

Info

Publication number
AR052567A1
AR052567A1 ARP060100410A ARP060100410A AR052567A1 AR 052567 A1 AR052567 A1 AR 052567A1 AR P060100410 A ARP060100410 A AR P060100410A AR P060100410 A ARP060100410 A AR P060100410A AR 052567 A1 AR052567 A1 AR 052567A1
Authority
AR
Argentina
Prior art keywords
bambuterol
pharmaceutically acceptable
integrine
inhibitor
combination
Prior art date
Application number
ARP060100410A
Other languages
English (en)
Inventor
Alexis Rames
Harpreet K Sandhu
David J Valacer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36097197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052567(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR052567A1 publication Critical patent/AR052567A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

Formas solidas de dosificacion farmacéutica para administracion oral que consiste en una cantidad terapéuticamente activa de bambuterol, o una sal farmacéuticamente aceptable del mismo, una cantidad terapéuticamente efectiva de éster de N-(2-cloro-6- metilbenzoil)-4-[(2,6-diclorobenzoil)amino]-L-fenilalanina-2-(dietilamino)etilo, o una sal farmacéuticamente aceptable del mismo y uno o más excipientes farmacéuticamente aceptables. Estas formas solidas de dosificacion farmacéutica son utiles en el tratamiento o control de asma.
ARP060100410A 2005-02-07 2006-02-06 Combinacion de bambuterol e inhibidor de integrina AR052567A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65066405P 2005-02-07 2005-02-07

Publications (1)

Publication Number Publication Date
AR052567A1 true AR052567A1 (es) 2007-03-21

Family

ID=36097197

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100410A AR052567A1 (es) 2005-02-07 2006-02-06 Combinacion de bambuterol e inhibidor de integrina

Country Status (4)

Country Link
US (1) US20060177503A1 (es)
AR (1) AR052567A1 (es)
TW (1) TW200638927A (es)
WO (1) WO2006081986A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007005601D1 (de) * 2006-01-18 2010-05-12 Hoffmann La Roche Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
CN104784131B (zh) * 2014-01-17 2018-09-21 南京瑞尔医药有限公司 一种盐酸班布特罗片剂的制备方法
CN104784128B (zh) * 2014-01-17 2018-09-21 南京瑞尔医药有限公司 一种盐酸班布特罗片剂组合物
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN113750061B (zh) * 2021-08-18 2022-12-23 河南省人民医院 一种班布特罗口崩片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1273A (en) * 1980-07-09 1985-03-08 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
SE9604752D0 (sv) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6455550B1 (en) * 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
RU2245874C2 (ru) * 1999-02-18 2005-02-10 Ф.Хоффман-Ля Рош Аг Производные тиоамида и фармацевтическая композиция
IL144641A0 (en) * 1999-02-18 2002-05-23 Hoffmann La Roche Phenylalaninol derivatives
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) * 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6734311B2 (en) * 2000-05-22 2004-05-11 Merck & Co., Inc. Substituted amidine derivatives as inhibitors of cell adhesion

Also Published As

Publication number Publication date
TW200638927A (en) 2006-11-16
WO2006081986A1 (en) 2006-08-10
US20060177503A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
AR052062A1 (es) Composicion y metodo para tratar el asma
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
ATE540690T1 (de) Insulinkombinationen
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR053154A1 (es) Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
DE602006012962D1 (de) Pharmazeutische Zubereitungen von Ciprofloxacin
RU2005131578A (ru) Аплидин для лечения множественной миеломы
SE0000303D0 (sv) Novel compounds
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
SE0203817D0 (sv) New composition
AR045074A1 (es) Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ATE402703T1 (de) Tablette enthaltend efletirizin und pseudoephedrin
RU2009107917A (ru) Аминоизохинолиновый ингибитор тромбина с улучшенной биодоступностью
CL2004000319A1 (es) Combinacion farmaceutica que comprende edotecarina o una sal farmaceuticamente aceptable y docetaxel o capacitabina, kit terapeutico, util para el tratamiento del cancer.
TR201700073A2 (tr) Di̇yabeti̇n tedavi̇si̇ i̇çi̇n terapöti̇k formülasyonlar

Legal Events

Date Code Title Description
FA Abandonment or withdrawal